Mon, Dec 29, 2014, 9:18 AM EST - U.S. Markets open in 12 mins.

Recent

% | $
Quotes you view appear here for quick access.

ADVANCED CELL TECH Message Board

  • binnieo binnieo Sep 7, 2013 9:52 PM Flag

    August article abstract by Dr Lanza, Dr Heilweil, Dr Schwartz and Carolyn Pan. Thought I had already posted it. oops.

    Expert Opinion on Biological Therapy
    Advanced Search

    Home
    All Issues
    Current Issue
    Early Online
    Aims & Scope
    Editorial Board
    Instructions for Authors

    Issue TOC | Previous Article | Next Article
    Reviews

    Embryonic stem cells as a treatment for macular degeneration
    August 2013, Vol. 13, No. 8 , Pages 1125-1133 (doi:10.1517/14712598.2013.793304)
    HTML
    PDF (244 KB)
    PDF Plus (319 KB)
    Reprints
    Permissions
    Carolyn K Pan 1 MD, Gad Heilweil 1 MD, Robert Lanza 2 MD & Steven D Schwartz †1
    1 University of California, Jules Stein Eye Institute, Retina Division, 200 Stein Plaza, Los Angeles, CA 90095, USA +1 310 206 7474; +1 310 825 3350; schwartz@jsei.ucla.edu
    2 Advanced Cell Technology, Marlborough, MA 01605, USA
    †Author for correspondence

    Introduction: Retinal degenerations are typically characterized by loss of highly differentiated cell types within the neurosensory retina, such as photoreceptors, or retinal pigment epithelium (RPE). RPE loss is the final common pathway in a number of degenerations including the leading cause of new blindness in the developed world: age-related macular degeneration (AMD).

    Areas covered: This paper presents the pathophysiologic case for RPE transplantation with stem cell (SC)-derived tissue, a review of the preclinical data substantiating the hypothesis and the initial clinical trials safety data from early human trials.

    Expert opinion: Targeting the RPE for transplantation with SC-derived tissue presents a reasonable therapeutic opportunity in a variety of important, otherwise untreatable, blinding conditions. Success of cellular replacement strategies is contingent on finding a viable source of replacement cells, establishing a safe technique for delivery and survival of transplanted cells within the host, restoration of normal retinal architecture and stabilization or improvement of vision.

    Sentiment: Hold

 
ACTC
6.98Nov 13 12:19 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Iconix Brand Group, Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST